Developer docs
API playgroundTry for free, no card

Search company profiles

Avere Therapeutics

Full company profile

uuid02m3c4g

Namestring
Avere Therapeutics
Legal namestring
Avere Therapeutics
Websiteurl
averetx.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Avere Therapeutics is a clinical-stage biotechnology company headquartered at 2001 Market Street, Suite 2500, Philadelphia, Pennsylvania, with its corporate agreement governed under the laws of the Commonwealth of Massachusetts. The company is developing AVR-001, an oral, once-weekly interleukin-23 (IL-23) receptor antagonist positioned for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The core technical differentiator is the dosing profile: an oral small molecule administered once weekly rather than the injectable biologics that currently dominate the IL-23 inhibitor class, targeting improved adherence and patient convenience in chronic indications.

The company operates as a single-asset, pre-commercial developer with no approved products and no disclosed revenue. Its business model is the standard clinical-stage biotech path: advance AVR-001 through clinical development to regulatory approval, then commercialize either directly via specialty pharma distribution to physicians and payers, or via partnership/out-licensing of regional or global rights. No pricing model, payer strategy, or commercial channel is disclosed in the available data, and no manufacturing footprint or supply-chain architecture is referenced.

The most significant strategic event in the input is the announced merger in which Avere will acquire NextCure, a publicly traded NASDAQ-listed company (ticker reference IRX4G3), for an undisclosed amount, with a target close of 2026-07-14. The transaction is positioned to broaden Avere's corporate platform and provide public-market access for clinical execution. The company is privately held, no funding rounds or capital raises are disclosed, and no executive team or headcount data is provided in the input.

Short descriptiontext

Avere Therapeutics is a clinical-stage biotechnology company developing AVR-001, an oral once-weekly IL-23 receptor antagonist for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersConshohocken, United States
HQ citystring
Conshohocken
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IL-23 receptor antagonist, inflammatory disease therapy, oral biologic therapy, clinical-stage biopharmaceutical, immunology drug development
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotech. The company is developing AVR-001 for inflammatory diseases (psoriasis, ulcerative colitis, Crohn's disease, psoriatic arthritis). Revenue will be generated through prescription drug sales upon FDA approval and commercialization.

averetx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avere Therapeutics is developing AVR-001, a single clinical-stage oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) intended for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The candidate is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly oral dosing as an alternative to injectable IL-23 inhibitors. The company is pre-revenue and has no commercialized products as of the source data.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Avere Therapeutics is developing a single pharmaceutical product, AVR-001, an oral once-weekly IL-23 receptor antagonist. The company is focused on advancing this single drug candidate through clinical development for inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The product represents a potentially meaningful improvement in treatment through its convenient once-weekly pill format.

Product and service1 record
1AVR-001
CategoryInflammatory disease therapeutics — IL-23 receptor antagonist
Description

AVR-001 is an oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) in clinical development for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. It is engineered for higher, more consistent drug exposure and a longer half-life to enable weekly oral dosing as an alternative to injectable IL-23 inhibitors.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

NextCure and Avere Therapeutics announced a merger to advance the once-weekly oral IL-23 therapy (AVR-001). This strategic combination is designed to accelerate development of AVR-001, combining NextCure's capabilities with Avere's IL-23 inhibition technology platform. The merger represents a significant corporate development milestone for the combined entity.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Pfizer markets Velsipity (etrasimod), an oral S1P receptor modulator approved for ulcerative colitis, and has a broader immunology pipeline. It is an oral immunology peer whose commercial footprint in IBD will overlap with any future AVR-001 positioning.

TypeBroad incumbent
Description

Roche markets Actemra (tocilizumab) and has a broad immunology franchise including IL-pathway biologics. As a global immunology leader with deep commercial reach in psoriasis and IBD, Roche is a relevant broad incumbent shaping the standards Avere's therapy must exceed.

TypeEmerging player
Description

Galapagos has historically pursued oral immunology candidates (e.g., JAK and S1P programs) in IBD and inflammatory diseases. As a European specialty biotech focused on oral small-molecule immunology, it is an emerging peer whose development path and commercial scale are comparable to Avere's anticipated trajectory.

4Sun Pharmaceutical Industries
TypeDirect peer
Description

Sun Pharma markets Ilumya/Tildrakizumab, an approved IL-23 inhibitor for psoriasis and active psoriatic arthritis. As an established injectable competitor in Avere's lead dermatology indication, it shapes the competitive landscape Avere must enter.

TypeDirect peer
Description

Johnson & Johnson markets Tremfya (guselkumab), an approved IL-23 inhibitor in psoriasis, psoriatic arthritis, Crohn's, and ulcerative colitis, and is Protagonist's partner on the oral IL-23 peptide icotrokinra — making J&J both a direct injectable competitor and the steward of the most advanced oral IL-23 program competing with AVR-001.

6Bristol Myers Squibb
TypeEmerging player
Description

BMS markets Zeposia (ozanimod), an oral S1P modulator approved for ulcerative colitis and Crohn's disease, and is developing next-generation oral immunology candidates. It represents the oral immunology convenience benchmark Avere's oral IL-23 must compete against in IBD.

TypeBroad incumbent
Description

Takeda markets Entyvio (vedolizumab), a leading biologic for ulcerative colitis and Crohn's disease, and is a major IBD commercial player. While not an IL-23 program, Entyvio defines the IBD treatment paradigm Avere's oral IL-23 must position against.

TypeDirect peer
Description

Eli Lilly markets Omvoh (mirikizumab), an approved IL-23p19 inhibitor for ulcerative colitis and Crohn's disease. It directly competes in Avere's IBD target indications and represents the kind of large-pharma incumbent Avere will face commercially.

TypeDirect peer
Description

AbbVie markets Skyrizi (risankizumab), an approved IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is the largest commercial incumbent in Avere's exact target indications and the benchmark Avere must beat on efficacy, safety, and convenience.

TypeDirect peer
Description

Protagonist Therapeutics is developing icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist peptide partnered with Johnson & Johnson — the most direct competitor to AVR-001 given both programs pursue oral IL-23 inhibition for psoriasis and other inflammatory diseases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avere Therapeutics

Inflammatory Disease Biopharmaceuticalsaveretx.com

Avere Therapeutics is a clinical-stage biotechnology company developing AVR-001, an oral once-weekly IL-23 receptor antagonist for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.

What Avere Therapeutics does

Avere Therapeutics is a clinical-stage biotechnology company headquartered at 2001 Market Street, Suite 2500, Philadelphia, Pennsylvania, with its corporate agreement governed under the laws of the Commonwealth of Massachusetts. The company is developing AVR-001, an oral, once-weekly interleukin-23 (IL-23) receptor antagonist positioned for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The core technical differentiator is the dosing profile: an oral small molecule administered once weekly rather than the injectable biologics that currently dominate the IL-23 inhibitor class, targeting improved adherence and patient convenience in chronic indications.

The company operates as a single-asset, pre-commercial developer with no approved products and no disclosed revenue. Its business model is the standard clinical-stage biotech path: advance AVR-001 through clinical development to regulatory approval, then commercialize either directly via specialty pharma distribution to physicians and payers, or via partnership/out-licensing of regional or global rights. No pricing model, payer strategy, or commercial channel is disclosed in the available data, and no manufacturing footprint or supply-chain architecture is referenced.

The most significant strategic event in the input is the announced merger in which Avere will acquire NextCure, a publicly traded NASDAQ-listed company (ticker reference IRX4G3), for an undisclosed amount, with a target close of 2026-07-14. The transaction is positioned to broaden Avere's corporate platform and provide public-market access for clinical execution. The company is privately held, no funding rounds or capital raises are disclosed, and no executive team or headcount data is provided in the input.

Avere Therapeutics firmographics

Firmographics
Name
Avere Therapeutics
Legal name
Avere Therapeutics
Website
https://averetx.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
11–50 employees
Short description
Avere Therapeutics is a clinical-stage biotechnology company developing AVR-001, an oral once-weekly IL-23 receptor antagonist for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.
Ownership category
akta.pro rank

Avere Therapeutics industry classification

Industry
Product category
Inflammatory Disease Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • IL-23 receptor antagonist
  • Inflammatory disease therapy
  • Oral biologic therapy
  • Clinical-stage biopharmaceutical
  • Immunology drug development

Where Avere Therapeutics is headquartered

Location

Headquarters

HQ city
Conshohocken
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avere Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech. The company is developing AVR-001 for inflammatory diseases (psoriasis, ulcerative colitis, Crohn's disease, psoriatic arthritis). Revenue will be generated through prescription drug sales upon FDA approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Avere Therapeutics product offering

Product offering

Core offering

Avere Therapeutics is developing AVR-001, a single clinical-stage oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) intended for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The candidate is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly oral dosing as an alternative to injectable IL-23 inhibitors. The company is pre-revenue and has no commercialized products as of the source data.

Product overview

Avere Therapeutics is developing a single pharmaceutical product, AVR-001, an oral once-weekly IL-23 receptor antagonist. The company is focused on advancing this single drug candidate through clinical development for inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The product represents a potentially meaningful improvement in treatment through its convenient once-weekly pill format.

Differentiator

Problem solved

Functional benefit

Products and services

  • AVR-001 AVR-001 is an oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) in clinical development for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. It is engineered for higher, more consistent drug exposure and a longer half-life to enable weekly oral dosing as an alternative to injectable IL-23 inhibitors.

Companies that use Avere Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Avere Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Avere Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NextCureflagshipStrategic or Co-development Partner · 1 January 2025NextCure and Avere Therapeutics announced a merger to advance the once-weekly oral IL-23 therapy (AVR-001). This strategic combination is designed to accelerate development of AVR-001, combining NextCure's capabilities with Avere's IL-23 inhibition technology platform. The merger represents a significant corporate development milestone for the combined entity.

Scale indicators1 record

Recent moves2 records

Expansion highlights3 records

Avere Therapeutics competitors and assessment

Company assessment

Emerging players

  • Pfizer: Pfizer markets Velsipity (etrasimod), an oral S1P receptor modulator approved for ulcerative colitis, and has a broader immunology pipeline. It is an oral immunology peer whose commercial footprint in IBD will overlap with any future AVR-001 positioning.
  • Galapagos NV: Galapagos has historically pursued oral immunology candidates (e.g., JAK and S1P programs) in IBD and inflammatory diseases. As a European specialty biotech focused on oral small-molecule immunology, it is an emerging peer whose development path and commercial scale are comparable to Avere's anticipated trajectory.
  • Bristol Myers Squibb: BMS markets Zeposia (ozanimod), an oral S1P modulator approved for ulcerative colitis and Crohn's disease, and is developing next-generation oral immunology candidates. It represents the oral immunology convenience benchmark Avere's oral IL-23 must compete against in IBD.

Broad incumbents

  • Roche: Roche markets Actemra (tocilizumab) and has a broad immunology franchise including IL-pathway biologics. As a global immunology leader with deep commercial reach in psoriasis and IBD, Roche is a relevant broad incumbent shaping the standards Avere's therapy must exceed.
  • Takeda Pharmaceutical: Takeda markets Entyvio (vedolizumab), a leading biologic for ulcerative colitis and Crohn's disease, and is a major IBD commercial player. While not an IL-23 program, Entyvio defines the IBD treatment paradigm Avere's oral IL-23 must position against.

Direct peers

  • Sun Pharmaceutical Industries: Sun Pharma markets Ilumya/Tildrakizumab, an approved IL-23 inhibitor for psoriasis and active psoriatic arthritis. As an established injectable competitor in Avere's lead dermatology indication, it shapes the competitive landscape Avere must enter.
  • Johnson & Johnson: Johnson & Johnson markets Tremfya (guselkumab), an approved IL-23 inhibitor in psoriasis, psoriatic arthritis, Crohn's, and ulcerative colitis, and is Protagonist's partner on the oral IL-23 peptide icotrokinra — making J&J both a direct injectable competitor and the steward of the most advanced oral IL-23 program competing with AVR-001.
  • Eli Lilly: Eli Lilly markets Omvoh (mirikizumab), an approved IL-23p19 inhibitor for ulcerative colitis and Crohn's disease. It directly competes in Avere's IBD target indications and represents the kind of large-pharma incumbent Avere will face commercially.
  • AbbVie: AbbVie markets Skyrizi (risankizumab), an approved IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is the largest commercial incumbent in Avere's exact target indications and the benchmark Avere must beat on efficacy, safety, and convenience.
  • Protagonist Therapeutics: Protagonist Therapeutics is developing icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist peptide partnered with Johnson & Johnson — the most direct competitor to AVR-001 given both programs pursue oral IL-23 inhibition for psoriasis and other inflammatory diseases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Avere Therapeutics social profiles

Digital presence

Avere Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avere Therapeutics leadership team

Management profile

Number of profiles

Avere Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avere Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avere Therapeutics

What does Avere Therapeutics do?

Avere Therapeutics is developing AVR-001, a single clinical-stage oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) intended for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The candidate is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly oral dosing as an alternative to injectable IL-23 inhibitors. The company is pre-revenue and has no commercialized products as of the source data.

Is Avere Therapeutics a public or private company?

Avere Therapeutics is a private company. It is classified as unknown and is currently operating.

When was Avere Therapeutics founded?

Avere Therapeutics was founded in 2026. It employs 11 to 50 people.

Where is Avere Therapeutics based?

Avere Therapeutics is headquartered in Conshohocken, United States, in the North America region.

How does Avere Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Avere Therapeutics's main competitors?

Emerging players on record are Pfizer, Galapagos NV and Bristol Myers Squibb. Broad incumbents are Roche and Takeda Pharmaceutical. Direct peers are Sun Pharmaceutical Industries, Johnson & Johnson, Eli Lilly, AbbVie and Protagonist Therapeutics.

Does Avere Therapeutics have an API?

No public API is recorded for Avere Therapeutics.

What industry is Avere Therapeutics in?

Avere Therapeutics's product category is Inflammatory Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comNextCure stock rating reiterated at Buy by H.C. Wainwright By Investing.comH.C. Wainwright reiterated a Buy rating and $20.00 price target on NextCure Inc. after a 46% stock increase following its merger announcement with Avere Therapeutics. The merger includes a $320 million private placement and is expected to complete in the second half of 2026, aiming to support Avere's ongoing drug development, including trials for psoriasis and ulcerative colitis.MarketScreenerRTW Biotech's Avere to go public in US in reverse merger with NextCureRTW Biotech Opportunities Ltd announced that its portfolio holding Avere Therapeutics will go public through a reverse merger with Nasdaq-listed NextCure Inc. Avere plans to raise USD500 million in a private placement, in addition to a previously announced USD320 million placement, to support the development of its lead program AVR-001 for psoriasis and ulcerative colitis. This marks the fourth portfolio company RTW has taken public via reverse merger in 2026.MarketScreenerRTW Biotech to Inject $6 Million in Avere Therapeutics Ahead of Reverse MergerRTW Biotech Opportunities Ltd has injected $6 million into Avere Therapeutics ahead of an anticipated reverse merger. The investment supports Avere Therapeutics' development efforts as the two entities prepare to combine through the transaction. This move aligns with RTW's strategy to invest in transformative assets within the biopharmaceutical sector.Stock TitanAvere Therapeutics $500M Private Placement for AVR-001Avere Therapeutics announced a $500 million private placement to fund the development of its oral IL-23 therapy AVR-001. The funding, combined with an additional private placement, will support the company's operations into 2029 and is linked to its upcoming merger with NextCure, expected to complete in the second half of 2026.PR NewswireAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare investors to support the development of its oral IL-23 therapy, AVR-001. The financing, combined with a previous investment, is expected to fully fund the company's operations into 2029 and support a merger with NextCure, Inc. scheduled for late 2026.BioSpaceAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare investors, adding to a previously announced $320 million concurrent placement. The combined proceeds will fully fund Avere's operating plan into 2029 and support development of its lead program AVR-001. The company is also in an all-stock merger with NextCure, expected to close in the second half of 2026.MorningstarAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare investors, adding to a previously announced $320 million concurrent placement. The combined proceeds will fund operations through 2029 and support development of AVR-001, a once-weekly oral IL-23 antagonist. The company is also advancing an all-stock merger with NextCure, expected in the second half of 2026.Tech TimesLigaChem Gains Sole Control of B7-H4 Cancer Drug With Distinct Tumor-Killing MechanismLigaChem Biosciences assumed sole development authority over LNCB74, a B7-H4-targeting antibody-drug conjugate, after NextCure exited to preserve capital for its Avere Therapeutics merger. LNCB74 carries MMAE, a tubulin-disrupting payload distinct from the topoisomerase I inhibitors used in other B7-H4 programs, and is in a Phase 1 trial. LigaChem retains the only non-topo I option for B7-H4-expressing cancers.GlobeNewswireNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsNextCure reported Q2 2026 net loss of $14.9 million and cash of $20.1 million, and announced a proposed all-stock merger with Avere Therapeutics. The merger is expected to close in the second half of 2026, with Avere's private financing generating about $320 million in gross proceeds.MorningstarHalper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC is investigating Twin Vee PowerCats, NextCure, TriCo Bancshares, and First Hawaiian for potential securities law violations and fiduciary breaches. The firm notes that proposed deals could limit superior offers, with shareholder ownership percentages ranging from 1.21% to 65% in the combined companies.